Dr. Tam on Results of the CAPTIVATE Trial in CLL

Video
Conference|ASH Annual Meeting and Exposition

Constantine S. Tam, MD, MBBS, associate professor, Peter MacCallum Cancer Centre, discusses the results of the phase II CAPTIVATE study in chronic lymphocytic leukemia (CLL).

Constantine S. Tam, MD, MBBS, associate professor, Peter MacCallum Cancer Centre, discusses the results of the phase II CAPTIVATE study in chronic lymphocytic leukemia (CLL).

<<< View more from the 2019 ASH Annual Meeting

Related Videos
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Jean L. Koff, MD, MS
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
Changchun Deng, MD, PhD
Angela Jia, MD, PhD, of University Hospitals
Robert Wang, MD, of Fox Chase Cancer Center
Alexander Kutikov, MD, FACS, of Fox Chase Cancer Center
Roger Li, MD, of Moffitt Cancer Center
Related Content
Carlos Barrios, MD

Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer

May 17th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
Sibylle Loibl, MD, PhD, chair, German Breast Group, chief executive officer, GBG Forschungs GmbH

Addition of Denosumab to Neoadjuvant Chemo Does Not Lead to Significant iDFS Differences in Early Breast Cancer

May 17th 2024
Article
Talal Hilal, MD, MB, BCh

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

January 12th 2023
Podcast
T-DXd in HER2+ Metastatic Breast Cancer | Image Credit: © Axel Kock - stock.adobe.com

T-DXd Maintains Survival Advantage Over Physician’s Choice of Therapy in HER2+ Metastatic Breast Cancer

May 16th 2024
Article
Mafalda Oliveira, MD, PhD

Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer

May 16th 2024
Article